A randomized, placebo-controlled, double-blind phase iii trial investigating the efficacy and safety of incobotulinumtoxin A in the treatment of glabellar frown lines using a stringent composite endpoint

Dermatologic Surgery

Volumn 39, Issue 6, 2013, Pages 891-899

  William Hanke, C ^a   Narins, Rhoda S ^b   Brandt, Fredric ^c   Cohen, Joel L ^d   Donofrio, Lisa M ^e   Downie, Jeanine ^f   Heinz, Moritz ^g   Harrington, Laura ^h   McDaniel, David H ⁱ   Nestor, Mark ^j   Schlessinger, Joel ^k   Schlöbe, Andrea ^g   Taub, Amy ^l   Weiss, Robert A ^m  

^a Laser and Skin Surgery Center of Indiana   (United States)

^b Dermatology Surgery and Laser Center   (United States)

^c Dermatology Research Institute   (United States)

^d AboutSkin Dermatology and DermSurgery PC   (United States)

^e Savin Center   (United States)

^f Image Dermatology   (United States)

^g MERZ PHARMACEUTICALS GMBH   (Germany)

^h Medical Writer   (United Kingdom)

ⁱ Institute of Anti Aging Research   (United States)

^j Center for Clinical and Cosmetic Research   (United States)

^k LovelySkincom   (United States)

^l Advanced Dermatology   (United States)

^m Maryland Laser Skin and Vein Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; ARTICLE; BLEPHAROSPASM; CONTROLLED STUDY; CONTUSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EAR INFECTION; FACE PAIN; FACIAL NERVE PARALYSIS; FACIAL WRINKLE SCALE; FEMALE; GLABELLAR FROWN LINE; HEMATOMA; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NOSE OBSTRUCTION; PATIENT ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SINUS HEADACHE; SINUSITIS; TREATMENT RESPONSE; WRINKLE;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXINS, TYPE A; COSMETIC TECHNIQUES; DOUBLE-BLIND METHOD; FEMALE; FOREHEAD; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN AGING; YOUNG ADULT;

EID: 84878761463     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/dsu.12160     Document Type: Article

References (20)

1. Carruthers A, Carruthers J,. Botulinum toxin products overview. Skin Therapy Lett 2008; 13 (6): 1-4.
2. Ascher B, Zakine B, Kestemont P, Baspeyras M, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51 (2): 223-33.
3. Carruthers A, Carruthers J,. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005; 31 (10): 1297-303.
4. Carruthers A, Carruthers J, Said S,. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005; 31 (4): 414-22.
5. Carruthers JA, Lowe NJ, Menter MA, Gibson J, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46 (6): 840-9.
6. Lowe P, Patnaik R, Lowe N,. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol 2006; 55 (6): 975-80.
7. Monheit G, Carruthers A, Brandt F, Rand R,. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007; 33 (1 Spec No.): S51-9.
8. Carruthers A, Carruthers JDA,. The use of botulinum toxin to treat glabellar frown lines and other facial wrinkles. Cosmet Dermatol 1994; 7: 11-15.
9. ®. Drugs R D 2010; 10 (2): 67-73.
10. ®. Summary of Product Characteristics. Germany: Merz Pharmaceuticals GmbH, 2010.
11. Bigalke H,. Properties of pharmaceutical products of botulinum neurotoxins. In:, Jankovic J, Albanese A, Attassi MZ, et al., editors. Botulinum toxin-therapeutic clinical practice and science. Philadelphia (PA): Saunders Elsevier, 2009.
12. Panjwani N, O'Keeffe R, Pickett A,. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J 2008; 1 (1): 153-66.
13. Sattler G, Callander M, Grablowitz D, Walker T, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg 2010; 36 (S4): 2146-54.
14. Prager W, Wissmüller E, Kollhorst B, Williams S, et al. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study. Dermatol Surg 2010; 36 (s4): 2155-60.
15. Oliveira de Morais O, Matos R-FE, Vilela PL, Martins GC, et al. Comparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: a pilot study. J Drugs Dermatol 2012; 11 (2): 216-9.
16. Benecke R, Jost WH, Kanovsky P, Ruzicka E, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64 (11): 1949-51.
17. Roggenkämper P, Jost WH, Bihari K, Comes G, et al. Efficacy and safety of a new Botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113 (3): 303-12.
18. Honeck P, Weiss C, Sterry W, Rzany B,. Reproducibility of a four-point clinical severity score for glabellar frown lines. Br J Dermatol 2003; 149 (2): 306-10.
19. Carruthers A, Carruthers J, Lowe NJ, Menter A, et al. One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res 2004; 7: 1-20.
20. Imhof M, Kühne U,. A Phase III study of incobotulinumtoxinA in the treatment of glabellar frown lines. J Clin Aesthet Dermatol 2011; 4 (10): 28-34.